...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Arthritis & Rheumatism >Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis†
【24h】

Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis†

机译：长期依那西普治疗对某些类型的青少年特发性关节炎儿童生长的影响†

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ObjectiveTo evaluate the effects of long-term etanercept treatment, with or without methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA).MethodsWe conducted a 3-year, open-label, nonrandomized registry of 594 patients with polyarticular or systemic JIA treated with etanercept only, etanercept plus methotrexate, or methotrexate only. Height, weight, and body mass index (BMI) were assessed at baseline and at years 1, 2, and 3, using percentiles derived from US Centers for Disease Control and Prevention standardized growth charts.ResultsStatistically significant increases in the mean height percentiles from baseline were observed in etanercept-treated patients at year 3 (4.8 percentile points) and in patients treated with etanercept plus methotrexate at years 1, 2, and 3 (2.4, 3.3, and 5.6 percentile points, respectively). Statistically significant increases from baseline in the mean weight percentiles were observed at years 1, 2, and 3 in both the etanercept group (7.4, 10.0, and 13.0 percentile points) and the etanercept-plus-methotrexate group (2.9, 6.9, and 8.4 percentile points, respectively). Statistically significant increases from baseline in the mean BMI percentiles were observed in both the etanercept group (range 9.6–13.8 percentile points) and the etanercept-plus-methotrexate group (range 2.1–5.2 percentile points). The mean height, weight, and BMI percentiles did not change significantly in patients in the methotrexate-only group.ConclusionEtanercept treatment, with or without methotrexate, may contribute to the restoration of normal growth in children with JIA.
机译：目的评估长期接受依那西普治疗与未加甲氨蝶呤治疗对特发性幼年特发性关节炎（JIA）患儿生长的影响。方法我们对594例多关节或非小关节的患者进行了为期3年的开放标签，非随机登记仅使用依那西普，依那西普加氨甲蝶呤或仅使用甲氨蝶呤治疗的全身性JIA。身高，体重和体重指数（BMI）在基线以及第1、2和3年时使用美国疾病控制和预防中心标准化生长图表得出的百分位数进行评估。结果相对于基线的平均身高百分位数具有统计学意义的显着增加在第3年时接受依那西普治疗的患者（4.8％百分点）和在第1、2和3年时接受依那西普联合甲氨蝶呤治疗的患者（分别为2.4、3.3和5.6个百分点）观察到。依那西普组（7.4、10.0和13.0个百分点）和依那西普加甲氨蝶呤组（2.9、6.9和8.4）在第1、2和3年均观察到平均体重百分数的基线具有统计学意义的增加百分点）。依那西普组（9.6-13.8个百分点）和依那西普+甲氨蝶呤组（2.1-5.2个百分点）均观察到BMI平均百分数的基线显着增加。纯甲氨蝶呤组患者的平均身高，体重和BMI百分位数无显着变化。结论接受或不接受甲氨蝶呤治疗的依那西普治疗可能有助于JIA儿童恢复正常生长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号